GLP-1 receptor agonist (GLP-1RA), a novel hypoglycemic agent, not only promotes insulin synthesis and secretion, but also decreases glucagon secretion in cells while promoting insulin secretion from cells of the pancreas, reduces food intake, and delays gastric emptying
The 9mg and 12mg dose had a profile more consistent with semaglutide but again with more diarrhea
Underdosing might not help achieve desired outcomes, and overdosing can result in serious adverse events
Because GLP-1s are used primarily for non-addiction related diseases, and are used at such massive scale, they do not have the stigma that surrounds addiction-specific treatments
Figure 6, Panel C, presents a forest plot of HRs ranked from the greatest to least reduction in all-cause mortality
05 Injection-site reaction worsens Mild redness or swelling that resolves in minutes is common